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LA. Mieles, J.J. Fung, I. Yokoyama, J. McCauley, N. Singh, S. Todo, A.D. Gordon, and T.E. Starzl 
DURING the cyclosporine (CyA) era. results of liver transplantation in American veterans were wone 
than those obtained in the private sector.' Encounged 
with our initial experience at the Univenity of Pitts-
burgh.l.l a tri~ of liver transplantation under FK 506 was 
initiated at the Pittsburgh Veterans Aft'ain Medical Center 
(PV AMC). with the expectation of improving results in 
this group of patients. 
MATERIALS AND METHODS 
Patient Population 
From October 22. 1989 to April 17, 1991. atotal of29 consecutive 
liver transplants were perfonned in 27 patients under FK S06 and 
steroid immunosuppression. The minimal follow-up was 30 days 
in aU surviving patients. Patient demographics and indications for 
liver transplantation are shown in Table I. Other characteristics of 
the group disclosed in Table I include: the United Network for 
Orpn Sharing (UNOSl classification. the presence of previous 
abdominal surgery. and the number of patients with portal vein 
thrombosis and/or sclerosis requiring iliac vein grafts. 
Invnunosuppression 
FK 506. The fint seven patients received O.IS mil/kg of FK S06 
IV over 4 houn. and then 0.07S mwkg IV every 12 houn untiJ able 
to take oral medications. The remaining 20 patients received 0.10 
mg/kg as a continuous drip over 24 houn. again. until able to take 
oral medications. The oral dose in both groups was O.IS mg/kg 
every 12 houn. Dose adjustments were made according to the 
clinical coune. with the aim of maintalrungtrough levels between 
I and 2 nglmL dunng the lirst weeks aiter transplantallon. 
Suroids. All patients received I g of methylprednisolone 1m· 
mediately after rev8SCulanzation of the graft. In the fint seven 
patients this was follOwed by a rapid steroid taper from 200 mgto 
20 mg over S days. The remaining 20 patients were gjven 20 mg oi 
IV methylprednisolone Immediately after transplantation and 
daily thereafter 120 mg of prednisone once the oral route was 
reestablished I. During the subsequent months. the prednisone 
Table 1. ClYlrec:a.rtatIca of the 27 Uver Tranepl8nt R.....,.. 
DemographICS 
MaIeIfemale 
Melnage 
PrtIYIOUS upper abdOmIna' surgery 
Patients r8QUUlng portal vein gralls 
UNOS status. 4 or STAT 
DiagnosIS 
Postnec:IObC CIITtIOsIS 
Lunnec. c:antIOSIS 
Primary tcIIIftI8Ing cnoIMgIIII 
Primary blllllV Clrrnosat ana 
metaDOllC dlSOl'Cllt'S 
2710 
45.71 : 8.84 SO 
11127 (40-1.) 
S1OTE~KF 
14127 ER1~KF 
12127 (44,5%) 
8127 (24.6"'-) 
5127 (18.5%) 
2J27 E1K~D11KF 
dose was slowly tapered. Twelve patients (SQ95l were.completely 
weaned 011' steroids at J months to I year following transplanta· 
tion. Eleven patients (4S9(,l are stiU receivinglow-dose prednisone 
(average of 10.9 % 2.0 SE mWd. range S to 20l in addition to FK 
S06. 
a,M,lmmullo.Ju""n"Gllrs. One patient. initially transplanted 
under FK S06. was switched to CyA 3 months after transplanta-
tion because of severe anorexia. He did not improve after the 
switch-over. but remained on CyA and parenteral nutntion. No 
patients received azathioprine. 
Statistical Analysis 
Actuarial survival was detennined by the Kaplan-Meier method 
using BMDp·PC statistical software. Vernon pe·90 (BMDP. Los 
Angeles. Califl. 
RESULTS 
Patient and graft actuarial survival rates were 87.9% and 
84.5%, respectively (Fig I). at 6 months. and remained the 
same at 12 and 18 months. Two patients required retrans· 
plantation for primary nonfunction. No grafts were lost to 
rejection. 
There were a total of three deaths. all of them in the 
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Fig 1. Patient and graft actuanal sUMval defined by the Kaplan· 
Meier methOd. 
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postoperative period. These were due to multiple cerebral 
infarcts. disseminated aspergillosis. and necrotizing pan-
creatitis. The remaining 24 patients are alive and well with 
a mean follow-up of 321 :!: 35.) SE days (range 30 to 572). 
Rejecbon Episodes 
Nine patients 133.3%) did not have a single episode of 
rejection. Another nine patients 133.3%) received a total of 
nine methylprednisolone boluses for suspected but not 
histological proven rejection. The remaining nine patients 
133.3%) had a total of II episodes of acute rejection. Five 
episodes were managed with adjustment of the baseline 
immunosuppression. and five episodes with a bolus of 
methylprednisolone. in addition to adjusting the baseline 
immunosuppression. No steroid recycles were given. and 
on only one occasion was OKTJ required. 
On average. patients received a total of 0.6 methylpred-
nisolone I·g boluses during the follow.up period. 
Viral and Fungal Intecbons 
In addition to the patient who died of disseminated as-
pergillosis. fungal infection was present in two other cases. 
One patient. with uncontrolled biliary sepsis secondary to 
primary sclerosing cholangitis. developed multiple intra-
abdominal abscesses postoperatively which grew candida. 
He was successfully treated with amphotericin and open 
drainage of the abdomen. Another patient presented with 
cutaneous blastomycosis of the upper extremity 17 months 
after transplantation. He was treated with local excision. 
Eight patients (29.6%) developed cytomegalovirus 
(CMV) infections following the transplant. Four patients 
(\4.8%) developed asymptomatic CMV shedding. while 
the remaining 4 patients (14.8%) developed symptomatic 
disease and were successfully treated with gancyclovir. 
Five pattents presented with mucocutaneous herpes that 
responded to oral acyclovir. There were no Epstein-Barr 
virus Infections. 
Renal Function 
Illustrated in Fig 2 are the serum creatinine means = SE 
for all 27 patients at selected time points. Included are two 
patients who developed acute renal failure after transplan-
tation. which required temporary hemodialysis. Note the 
rise in serum creatinine during the first week posurans-
plant followed by a progressive decline during the subse-
quent weeks. The mean serum creatinines were 1.47 
mgldL = 0.)) SE at 3 months. 1.5 mgldL :!: 0.08 SE at 6 
months. and 1.36 mgtdL :!: 0.08 SE at 12 months. 
Diabetes. NeurotoxICIty. and Other Side Effects 
Two of the survIving 24 patients were insulin-dependent 
diabetics before and remained so after transplantation. Of 
the 22 patients who were nondiabetic. 4 (18%) developed 
posttransplant diabetes. although only 2 have required 
insulin therapy. 
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Fig 2. The mean serum creatinine = standard error of the mean 
(SEl at selected time points in the 27 liver transplant reaplents. 
None of the patients suffered from serious neurotoxicity 
episodes such as seizures. unconsciousness. or expressive 
aphasia. Several patients had minor side effects such as 
photophobia. insomnia. headaches. etc. all of which sub-
sided or significantly improved after appropriate dose 
adjustments of the FK 506. 
DISCUSSION 
In reviewing the literature. two institutions have reponed 
results of liver transplantation under CyA in veterans. In 
one repon. 16 veterans and 3) private patients were 
analyzed together. Although the I-year actuarial survival 
was 80%. no reference was made to the outcome of the 
veterans as a group.4 
A second repon analyzed 67 veterans who were trans-
planted and managed at our hospital (Presbytenan-Uni-
versity Hospital of Pittsburgh). Although the reasons for 
the outcome reponed here were not clearly identified. their 
conclusion was that the results of liver transplantation 
(67% actuarial survival) obtained in veterans were not as 
good as those obtained in the civilian sector. 1 
In this study. we present a group of 27 veterans trans-
planted under FK 506 immunosuppression. All were trans-
planted and managed at a veterans affairs facility. As 
shown in Table I. this was not a panicularly low-risk group 
of patients: 51% had a high UNOS score. 40% had 
previous upper abdominal sUllery. and 2:!% required 
ponal vein grafts. Therefore. an actuarial survival of 
87.9% under FK 506 immunosuppression compares favor-
ably to the 67% obtained under eyA. 
Few patients required additional immunosuppression. 
such as OKTJ and/or steroid recycles. which may explain 
lhe low incidence of CMV and other opponunistic infec-
lions. The incidence of CMV infection reponed here was 
only half of that reponed under CyA.5 and similar to the 
incidence reponed by Alessianill in the University of 
Pittsburgh FK 506 trials. 
Although a potent immunosuppressant. FK 506 has 
shown an acceptable therapeutic index. at least in our 
experience. since: (I) no pauent experienced senous neu-
rotoxicity; (21 the 18% incidence of posttransplant diabetes 
3018 
is within the expected range for organ transplantation 7 -II : 
and (3) the moderate degree of nephrotoxicity is similar to 
that reponed by the University of Pittsburgh in the ran-
domized trials, for both FK S06 and Cy A. II 
REFERENCES 
t. Leventhal RI. Berman DH. W1ty S. et aJ: Dig Dis Sci 
3.5:673. 1990 
2. FUIII JJ. Todo S. Jain A. et &1: Transplant Pro<: 22:6. 1990 
3. Todo S. FUIIIJJ. Demetris Al. etaJ: Transplant Proc: 22:13. 
1990 
4. Pinson CWo Lopez RR. Benner KG. et aJ: Am J Surg 
161:606. 1991 
MIElES. FUNG. YOKOYAMA ET AL 
.5. Singh N. Dummer JS. Kusne S. et a1: J Infect Dis 1.58:124 
1988 .' 
6. Alessiani M. Kusne S. Manin M. et aJ: Transplant Proc 
23:1.501. 1991 
7. Yoshimura N. Nakai I. Ohmon Y. et aJ: Am J Kidney Dis 
12(1): II. 1988 
8. Boudreaux JP. McHugh L. Canafax W. et aJ: Transplanta. 
tion 44:376. 1987 
9. Roth D. Milgram M. Esquenazi. et aJ: Transplantation 
47:278. 1989 
10. Mieles L. Gordon RD. Mintz D. et a1: Transplant Proc 
23:949. 1991 
II. Fun, J, Abu-Elmagd K. Jain A. et a1: Transplant Proc: (in 
press) 
